Literature DB >> 26059451

STAT5A regulates DNMT3A in CD34(+)/CD38(-) AML cells.

Asako Takeuchi1, Chie Nishioka2, Takayuki Ikezoe3, Jing Yang2, Akihito Yokoyama2.   

Abstract

Signal transducer and activator of transcription 5 (STAT5) is activated in CD34(+)/CD38(-) acute myelogenous leukemia (AML) cells. Inhibition of STAT5 induced apoptosis and sensitized these cells to the growth inhibition mediated by conventional chemotherapeutic agents. The present study attempted to identify molecules that are regulated by STAT5 in CD34(+)/CD38(-) AML cells by utilizing cDNA microarrays, comparing the gene expression profiles of control and STAT5A shRNA-transduced CD34(+)/CD38(-) AML cells. Interestingly, DNA methyltransferase (DNMT) 3A was downregulated after depletion of STAT5A in CD34(+)/CD38(-) AML cells. Reporter gene assays found that an increase in activity of DNMT3A occurred in response to activation of STAT5A in leukemia cells. On the other hand, dephosphorylation of STAT5A by AZ960 decreased this transcriptional activity. Further studies utilizing a chromatin immunoprecipitation assay identified a STAT5A-binding site on the promoter region of DNMT3A gene. Forced expression of STAT5A in leukemia cells caused hypermethylation on the promoter region of the tumor suppressor gene, PTEN, and downregulated its mRNA levels, as measured by methylation-specific and real-time polymerase chain reaction, respectively. Taken together, these data suggest that STAT5A positively regulates levels of DNMT3A, resulting in inactivation of tumor suppressor genes by epigenetic mechanisms in AML cells.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AML; DNMT3A; PTEN; STAT5A

Mesh:

Substances:

Year:  2015        PMID: 26059451     DOI: 10.1016/j.leukres.2015.05.006

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  7 in total

1.  STAT5BN642H is a driver mutation for T cell neoplasia.

Authors:  Ha Thi Thanh Pham; Barbara Maurer; Michaela Prchal-Murphy; Reinhard Grausenburger; Eva Grundschober; Tahereh Javaheri; Harini Nivarthi; Auke Boersma; Thomas Kolbe; Mohamed Elabd; Florian Halbritter; Jan Pencik; Zahra Kazemi; Florian Grebien; Markus Hengstschläger; Lukas Kenner; Stefan Kubicek; Matthias Farlik; Christoph Bock; Peter Valent; Mathias Müller; Thomas Rülicke; Veronika Sexl; Richard Moriggl
Journal:  J Clin Invest       Date:  2017-12-04       Impact factor: 14.808

Review 2.  Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.

Authors:  Anna Orlova; Bettina Wingelhofer; Heidi A Neubauer; Barbara Maurer; Angelika Berger-Becvar; György Miklós Keserű; Patrick T Gunning; Peter Valent; Richard Moriggl
Journal:  Expert Opin Ther Targets       Date:  2017-11-24       Impact factor: 6.902

3.  MicroRNA-9 plays a role in interleukin-10-mediated expression of E-cadherin in acute myelogenous leukemia cells.

Authors:  Chie Nishioka; Takayuki Ikezoe; Bin Pan; Kailin Xu; Akihito Yokoyama
Journal:  Cancer Sci       Date:  2017-04-20       Impact factor: 6.716

4.  Metastasis-associated protein 1 is an upstream regulator of DNMT3a and stimulator of insulin-growth factor binding protein-3 in breast cancer.

Authors:  S Deivendran; Hezlin Marzook; T R Santhoshkumar; Rakesh Kumar; M Radhakrishna Pillai
Journal:  Sci Rep       Date:  2017-04-10       Impact factor: 4.379

Review 5.  One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies.

Authors:  Antonia Kalushkova; Patrick Nylund; Alba Atienza Párraga; Andreas Lennartsson; Helena Jernberg-Wiklund
Journal:  Epigenomes       Date:  2021-10-08

6.  Dnmt3a is downregulated by Stat5a and mediates G0/G1 arrest by suppressing the miR-17-5p/Cdkn1a axis in Jak2V617F cells.

Authors:  Jie Zhou; Cheng Guo; Hao Wu; Bing Li; Li-Li Zhou; Ai-Bin Liang; Jian-Fei Fu
Journal:  BMC Cancer       Date:  2021-11-13       Impact factor: 4.430

Review 7.  Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer.

Authors:  Bettina Wingelhofer; Heidi A Neubauer; Peter Valent; Xiaonan Han; Stefan N Constantinescu; Patrick T Gunning; Mathias Müller; Richard Moriggl
Journal:  Leukemia       Date:  2018-03-27       Impact factor: 11.528

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.